Israel ischemic heart disease (IHD) Drugs Market is expected to grow at
an impressive rate during the forecast period, 2024-2028. The major factors include the rising prevalence of chronic diseases such as cardiovascular
diseases, cancer, and diabetes and the growing adoption of technological
advancement. The increasing awareness of the masses toward interventional
medical procedures along with extensive utilization of anti-anginal medications
for the treatment of ischemic heart diseases is one of the key factors driving
the growth of the Israel ischemic heart diseases market. Additionally, the
unhealthy lifestyle and lack of physical activity are projected to promote the
growth of the Israel ischemic heart disease (IHD) drugs market during
the forecast period. According to World Health Organization 2020, diabetes
mellitus deaths in Israel reached to around 1,913 or 5.44% of total deaths. The
age adjusted death rate is 13.96 per 100,000 of population.
Ischemic heart
disease is a condition that occurs when the blood supply to the heart is
reduced or blocked, leading to damage of heart muscle tissue. This is mostly
caused by atherosclerosis, a buildup of plaque in the arteries that supply
blood to the heart, which can narrow or block these arteries. The most common
symptom of ischemic heart disease is angina in which the heart does not get
proper oxygen. Risk factors for ischemic heart disease include age, smoking,
high blood pressure, high cholesterol, diabetes, family history, and a
sedentary lifestyle.
The rise in
awareness related to complications associated with heart disease is a major
factor that fuels the growth of the Israel
ischemic heart disease (IHD) drugs market. Moreover, the increase in
geriatric population and sedentary lifestyle boost the growth of the market.
However, high cost of drugs, alternative therapies, and change in lifestyle are
anticipated to hinder the growth of the Israel ischemic heart diseases market.
Conversely, the rise in healthcare infrastructure is expected to offer
lucrative opportunities to the market players during the forecast period.
Rising Prevalence of Ischemic Heart Disease
The increasing prevalence of ischemic heart disease drugs in Israel is
driven by a combination of factors. These include the high prevalence of heart
issues in the country, the aging population, and the growing demand for
effective treatments. In addition, the Israeli government has launched several
initiatives to improve the prevention and management of cardiovascular
diseases, including ischemic heart disease. For instance, according to the
World Health Organization (WHO), ischemic heart disease accounted for
approximately 8.9 million deaths in 2019. The increasing prevalence of risk
factors such as obesity, diabetes, and high blood pressure has contributed to
the rising incidence of ischemic heart disease, which, in turn, drives the
demand for drugs to treat and manage the condition, thereby propelling the
growth of the Israel ischemic heart disease (IHD) drugs market. For
instance, according to the research articles, around half (49%) of the patients
with heart failure had ischemic heart disease, 44% had irregular heart rhythm
(atrial fibrillation), and 34.5% had diabetes.
Many Israelis have adopted healthier lifestyles, including increased
physical activity and healthier diets, which can help prevent and manage
cardiovascular disease. However, lifestyle changes may not be enough to prevent
or manage the condition in all cases, and drugs may be necessary to control
symptoms and prevent complications. Moreover, the increasing prevalence of
ischemic heart disease drugs in Israel is driven by a combination of factors,
including the high prevalence of the condition, the aging population, advances
in drug development and technology, government initiatives, and lifestyle
changes. Thus, with the increasing demand for effective drugs to treat and
manage ischemic heart diseases, the growth of the Israel ischemic heart disease
(IHD) drugs market is projected to grow during the forecast period.
Development of Healthcare Infrastructure
Israel is known for its innovative and advanced
healthcare infrastructure, and the country has a thriving pharmaceutical
industry. Advances in drug development and technology have led to the
introduction of new and improved drugs to treat ischemic heart disease, which
is subjected to propel the growth of the Israel ischemic heart disease (IHD) drugs market. Several
other factors that will boost the growth of the Israel ischemic heart disease
(IHD) drugs market include growing initiatives by private and government
organizations and rising awareness for drugs with its maximum efficacy to treat
ischemic heart diseases. A few organizations dealing with the products of heart
diseases drugs have taken initiatives to conduct a camp and checked the blood
pressure and made them aware of various aspects of high blood pressure. Such
factors have driven the growth of the Israel
ischemic heart disease (IHD) drugs market. A major Israel’s healthcare authority is the
National Health Insurance Law, which allows every resident to choose 1 of 4
health plans regardless of age, pre-existing conditions, or health status. The
different quality measures of essential cardiovascular therapeutics are monitored
by health maintenance organizations and by the Medical Quality Division of the
Ministry of Health in Israel. The government had developed a society called Israel
Heart Society which is a member of the European Society of Cardiology to
promote the prevention and treatment of heart diseases, encourage professional
and scientific knowledge and education, increase the awareness of
cardiovascular health, and advocate for cardiovascular therapeutic. The Israel
Heart Society conducts national surveys to describe cardiac health status and
trends in therapeutic management. The most established survey is the Acute
Coronary Syndrome Israeli Survey. All these efforts across the country are responsible
for propelling the growth of Israel ischemic heart diseases drugs market.
Public health campaigns have also played a role in
increasing awareness of the health risks associated with ischemic heart disease
in Israel. These campaigns aim to educate the public about the importance of
healthy lifestyle choices, such as diet and exercise. They also encourage
people to get their blood pressure checked regularly and to seek medical
treatment if their blood pressure is high. To increase awareness of ischemic
issues in Israel, a few outreach programs, educational efforts, and public
health campaigns have been taken forward. The main objectives of these programs
are to inform the public about the causes of ischemic heart diseases, the value
of healthy heart, and the advantages of treatments and formulation of drugs. The
Israel’s Ministry of Health has also taken steps to address the growing
prevalence of cardiovascular diseases by implementing national guidelines for
the prevention, diagnosis, and treatment of the condition. These initiatives
aim to increase awareness, improve access to healthcare, and support research
and development in the field of ischemic heart stroke, which, in turn, will
drive the growth of the Israel ischemic heart disease (IHD) drugs market during
the forecast period.
Download Free Sample Report
Market
Segmentation
The Israel ischemic
heart disease (IHD) drugs market can be segmented by disease
class, drug class, and region. By disease class, the market can be segmented into angina
pectoris, myocardial infarction. Based on drug class, the market can be segmented into anti-dyslipidemic drugs, calcium channel
blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic
agents.
Market Players
Pfizer
Pharmaceuticals Israel Ltd, MERCK SERONO LTD., GlaxoSmithKline Israel Ltd, Bayer-Israel,
Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, Eli Lilly Israel, Actelion
Pharmaceuticals Israel Ltd, Bristol-Myers Squibb Israel Ltd, and Roche
Pharmaceuticals (Israel) Ltd.. are some of the leading companies operating in
the Israel ischemic heart disease (IHD) Drugs Market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2022
|
|
Estimated Year
|
2022
|
|
Forecast Period
|
2023 – 2028
|
|
Quantitative
Units
|
Revenue in USD Million, Volume Units and CAGR for 2018-2022
and 2023-2028
|
|
Report coverage
|
Revenue forecast, Volume forecast company share, competitive
landscape, growth factors, and trends
|
|
Segments
covered
|
- Disease Class
- Drug Class
- Region
- Company
|
|
Regional scope
|
The Mediterranean coastal plain, The Central Hills, The Jordan Rift
Valley, and The Negev Desert
|
|
Key companies
profiled
|
Pfizer
Pharmaceuticals Israel Ltd, MERCK SERONO LTD., GlaxoSmithKline Israel Ltd,
Bayer-Israel, Novartis Pharma Israel Ltd, Sanofi-Aventis Israel Ltd, Eli
Lilly Israel, Actelion Pharmaceuticals Israel Ltd, Bristol-Myers Squibb
Israel Ltd, and Roche Pharmaceuticals (Israel) Ltd
|
|
Customization scope
|
10% free report customization with purchase. Addition or alteration to
country, regional & segment scope.
|
|
Pricing and
purchase options
|
Avail
customized purchase options to meet your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email (We can also provide the editable version
of the report in PPT/Word format on special request)
|
Report Scope:
In this report, the
Israel ischemic heart disease (IHD) Drugs Market has been segmented into following
categories, in addition to the industry trends which have also been detailed
below:
- Israel ischemic heart
disease (IHD) Drugs Market, By Disease Class
- Angina Pectoris
- Myocardial Infarction
- Israel ischemic heart disease (IHD) Drugs Market,
By Drug Class
- Anti-Dyslipidemic Drugs
- Calcium Channel Blockers
- Beta-Blockers
- ACE Inhibitors
- ARBs
- Vasodilators
- Antithrombotic Agents
- Israel ischemic heart disease (IHD) Drugs Market,
By Region:
- The Mediterranean coastal plain
- The Central Hills
- The Jordan Rift Valley
- The Negev Desert
Competitive
Landscape
Company
Profiles: Detailed analysis of the major companies present
in the Israel ischemic heart disease (IHD) drugs market.
Available
Customizations:
With the given
market data, TechSci Research offers customizations according to a company’s
specific needs. The following customization options are available for the
report:
Company
Information
- Detailed analysis and profiling of additional
market players (up to five).
Israel ischemic heart disease IHD Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected].